<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986193</url>
  </required_header>
  <id_info>
    <org_study_id>Skejby 2008-1</org_study_id>
    <nct_id>NCT00986193</nct_id>
  </id_info>
  <brief_title>Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis</brief_title>
  <official_title>Randomized Comparison of Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised comparison of apical stent valve treatment versus conventional
      valve surgery in patients with severe aortic valve stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare the new established apical stent valve treatment with
      conventional surgical intervention using biological valve prostheses in patients with severe
      aortic valve stenosis.

      The Edwards-SAPIENTM Transcatheter Heart Valve (Edwards Lifesciences, Irvine, CA) will be
      used in the stent valve group. The Carpentier-Edwards-Perimount Heart Valve (Edwards
      Lifesciences, Irvine, CA) will be recommended for the conventional surgery group.(Edwards
      Lifesciences, Irvine, CA).

      Heart centres in the Nordic region with experience (&gt;10 cases) in apical stent valve
      treatment and in conventional surgical treatment of high risk patients with aortic valve
      stenosis. The study will be initiated at Aarhus University Hospital, Skejby, Denmark.

      Study hypothesis:

      As compared to conventional aortic valve substitution in patients aged &gt;75 years, apical
      stent valve treatment reduces the rates of death, cerebrovascular insult (CVI) and need of
      dialysis for renal failure 1 month after the treatment.

      Primary clinical end-point:

      Combined end-point consisting of death, CVI and/or renal failure with need for haemodialysis,
      1 month after index treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    By recommendation from the Data and safety monitoring board
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, CVI and/or renal failure requiring any dialysis</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic results, valve performance</measure>
    <time_frame>1 month with subseguent followup</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Conventional Aortic Valve Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of a biological valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transapical Aortic Valve Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transapical implantation of an Edwards SAPIENtm valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transapical Aortic Valve Implantation</intervention_name>
    <description>Insertion of a stent valve using catheter-based technique through a mini thoracotomy</description>
    <arm_group_label>Transapical Aortic Valve Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Aortic Valve Surgery</intervention_name>
    <description>Operation using heart-lung machine, with insertion of a biological artificial heart valve</description>
    <arm_group_label>Conventional Aortic Valve Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Significant aortic valve stenosis (valve area &lt; 1cm2)

          -  Age &gt; 75 (years Aarhus University Hospital, Skejby)

          -  Age &gt; 80 years (other participating centres)

          -  Operable by conventional surgery AND transapical stent valve implantation

          -  Expected survival &gt; 1 year following successful treatment

          -  Accept of participation and in follow-up investigations after adequate information

          -  Informed consent

        Exclusion Criteria:

          -  Coronary artery disease requiring PCI or CABG

          -  Earlier cardiac surgery

          -  Myocardial infarction within 24 hours

          -  Kidney failure requiring any dialysis

          -  Ongoing infection

          -  Acute surgery

          -  Allergy to ASA or Clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evald H Christiansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skejby Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus N</city>
        <state>Region Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Stent Valve</keyword>
  <keyword>Biological Aortic Valve Prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

